真性红细胞增多症治疗范式转变:早期初始使用重组干扰素α
综述指出,重组干扰素α(rIFNα)在真性红细胞增多症(PV)中可改善症状、缩小脾脏、纠正血象及骨髓形态并实现JAK2V617F分子缓解。PROUD-CONTI研究显示rIFNα优于羟基脲(HU),Low-PV试验显示ropegIFN优于单纯放血,支持对低危和高危PV患者早期初始使用rIFNα。
要点
- rIFNα可实现PV的症状缓解、脾脏缩小、血象及骨髓形态正常化和JAK2V617F分子缓解。
- PROUD-CONTI显示rIFNα优于HU,Low-PV显示ropegIFN优于单纯放血。
- NCCN将ropegIFN列为ELN定义低危和高危PV的II-A推荐。
核心结论
- 综述支持对低危和高危PV患者早期初始使用rIFNα,除非存在禁忌证。
研究设计与样本
- 综述总结了35年间rIFNα治疗PV的单臂研究及PROUD-CONTI、Low-PV随机试验证据。
主要发现
- 部分患者经2-5年疾病修饰治疗获得症状缓解、脾大消退、异常血象和骨髓形态正常化及持续JAK2V617F分子缓解。
- PROUD-CONTI研究显示rIFNα优于羟基脲(HU),Low-PV随机试验显示ropegIFN优于单纯放血(PHLEB-O)。
- 低危PV患者血栓风险仍约为一般人群的2至3倍,PV进展中骨髓纤维化是主要致病原因,单纯放血可能促进其发生。
关键数值与推荐
- 2019年欧洲药品管理局批准ropeginterferon alpha-2b(ropegIFN)用于ELN定义的高危PV患者。
- 2021年美国FDA批准ropegIFN不限适应人群,但妊娠PV患者除外。
- NCCN将ropegIFN列为ELN定义低危和高危PV的II-A推荐。
- ELN建议低危患者在接受单纯放血后出现更多症状、进行性脾大、显著白细胞增多、血小板增多或血细胞比容控制不佳时使用rIFNα。
临床怎么用
- 对低危和高危PV患者可考虑早期初始使用rIFNα,除非存在禁忌证。
- 低危PV患者单纯放血后出现症状加重、脾大进展、显著白细胞或血小板增多或血细胞比容控制不佳时,应启用rIFNα。
局限性
- 全球范围内HU仍是PV最常用的细胞减灭药物,部分血液科医生仍认可维持性单纯放血治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the past 35 years, single-arm studies documented the efficacy and safety of recombinant interferon alpha (rIFNα) for treating polycythemia vera (PV). In some patients, 2-5 years of disease-modifying treatment resulted in symptom relief, regression of splenomegaly, normalization of abnormal blood counts and marrow morphology, and sustained JAK2V617F molecular remission. The PROUD-CONTI study showed the superiority of rIFNα compared to hydroxyurea (HU), which led to the European Medicines Agency approval in 2019 of ropeginterferon alpha-2b ("ropegIFN") for ELN-defined high-risk PV patients. In 2021, the Food and Drug Administration (USA) gave unrestricted approval, except for pregnant PV patients. The Low-PV randomized trial established the superiority of ropegIFN compared to phlebotomy-only (PHLEB-O) in ELN-defined low-risk patients. Nevertheless, worldwide, HU remains the cytoreductive drug most often used; maintenance PHLEB-O is still endorsed as maintenance therapy by some hematologists. The National Comprehensive Cancer Network (NCCN, USA) approved ropegIFN as a II-A recommendation for ELN-defined low and high-risk disease; the ELN suggested criteria for using rIFNα in low-risk patients if certain issues developed after PHLEB-O, including more symptoms, progressive splenomegaly, significant leukocytosis, thrombocytosis, or inadequate hematocrit control. These issues are important because even low-risk patients are at increased thrombotic risk, estimated at 2 to 3 times that of the general population. Moreover, as PV progresses, the development of myelofibrosis is the leading cause of morbidity, perhaps abetted by PHLEB-O. Here, we review recent progress in the treatment of PV with rIFNα and discuss our rationales and perspectives for, and the endorsement of the initial treatment with rIFNα of both low and high-risk PV patients, unless a contraindication exists to its use.
引用
- Silver RT, Hasselbalch HC. A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha. Leukemia. 2026. PMID: 41951941. doi:10.1038/s41375-026-02882-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。